Table 1 (Abstract 40). Baseline patient characteristics
Age, years Mean (SD), Range | 13.3+/−3.5; 3.4–18 |
|---|---|
Disease duration, years Mean (SD), Range | 7.9+/−4.1; 0.4–16 |
JIA category, n;% | |
RF+ polyarthritis | 6; 8% |
RF- polyarthritis | 39; 49% |
Ext. oligoarth. | 21; 27% |
ERA-JIA | 5; 6% |
Juv. psoriatic arthritis | 5; 6% |
Systemic onset JIA | 3; 4% |
Concomitant Tx | |
Methotrexate | 29; 37% |
Sulfasalazine | 1; 1% |
Leflunomide | 1; 1% |
Corticosteroids | 15; 19% |
Pretreatment, n, % | |
Methotrexate | 79; 100% |
Abatacept | 8; 11% |
Adalimumab | 51; 65% |
Anakinra | 3; 4% |
Canakinumab | 2; 3% |
Etanercept | 45; 57% |
Golimumab | 34; 43% |
Infliximab | 1; 1% |
Secukinumab | 5; 6% |
Tocilizumab | 45; 57% |
bDMARD pretreatment, n, % | |
None | 7 (9%) |
1 | 13 (16%) |
2 | 18 (23%) |
3 | 22(28%) |
4 | 14 (18%) |
5 | 4 (5%) |
6 | 1 (1%) |